Literature DB >> 24106070

Exogenous Vasopressin-Induced Hyponatremia in Patients With Vasodilatory Shock: Two Case Reports and Literature Review.

Miguel Salazar1, Bee Bee Hu2, Joyce Vazquez3, Ruth L Wintz4, Joseph Varon5.   

Abstract

Vasopressin has gained wide support as an adjunct vasopressor in patients with septic shock. This agent exerts its vasoconstriction effects through smooth muscle V1 receptors and also has antidiuretic activity via renal V2 receptors. This interaction with the renal V2 receptors results in the integration of aquaporin 2 channels in the apical membrane of the renal collecting duct leading to free water reabsorption. Thus, water intoxication with subsequent hyponatremia, although rare, is a potentially serious side effect of exogenous vasopressin administration. We present 2 patients who developed hyponatremia within hours of initiation of vasopressin infusion. Extensive diuresis followed its discontinuation with subsequent normalization of serum sodium. One of the patients required the use of hypertonic saline for more rapid normalization of serum sodium due to concerns for potential seizure activity. A review of the literature relevant to the incidence of vasopressin-induced hyponatremia is provided as well as discussion on additional factors relevant to septic shock that should be considered when determining the relative risk of hyponatremia in patients receiving vasopressin.
© The Author(s) 2013.

Entities:  

Keywords:  antidiuresis; hyponatremia; vasodilatory shock; vasopressin; vasopressors

Mesh:

Substances:

Year:  2013        PMID: 24106070     DOI: 10.1177/0885066613507410

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  8 in total

1.  Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.

Authors:  Zi-Meng Liu; Juan Chen; Qiuye Kou; Qinhan Lin; Xiaobo Huang; Zhanhong Tang; Yan Kang; Ke Li; Lixin Zhou; Qing Song; Tongwen Sun; Ling Zhao; Xue Wang; Xiandi He; Chunting Wang; Benquan Wu; Jiandong Lin; Shiying Yuan; Qin Gu; Kejian Qian; Xianqing Shi; Yongwen Feng; Aihua Lin; Xiaoshun He; Xiang-Dong Guan
Journal:  Intensive Care Med       Date:  2018-07-03       Impact factor: 17.440

2.  Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: A Randomized Control Study.

Authors:  Pallavi Sahoo; Nikhil Kothari; Shilpa Goyal; Ankur Sharma; Pradeep K Bhatia
Journal:  Indian J Crit Care Med       Date:  2022-06

3.  Risk of Hyponatremia in Patients with Aneurysmal Subarachnoid Hemorrhage Treated with Exogenous Vasopressin Infusion.

Authors:  Nancy Marr; Jessica Yu; Demetrios J Kutsogiannis; Sherif Hanafy Mahmoud
Journal:  Neurocrit Care       Date:  2017-04       Impact factor: 3.210

Review 4.  Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans.

Authors:  James E Blevins; Denis G Baskin
Journal:  Physiol Behav       Date:  2015-05-23

5.  Terlipressin for septic shock patients: a meta-analysis of randomized controlled study.

Authors:  Yibing Zhu; Huibin Huang; Xiuming Xi; Bin Du
Journal:  J Intensive Care       Date:  2019-03-12

6.  Clinical Efficiency of Vasopressin or Its Analogs in Comparison With Catecholamines Alone on Patients With Septic Shock: A Systematic Review and Meta-Analysis.

Authors:  Ren-Qi Yao; De-Meng Xia; Li-Xue Wang; Guo-Sheng Wu; Yi-Bing Zhu; Hong-Qiang Zhao; Qi Liu; Zhao-Fan Xia; Chao Ren; Yong-Ming Yao
Journal:  Front Pharmacol       Date:  2020-05-06       Impact factor: 5.810

7.  Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis.

Authors:  Po Huang; Yuhong Guo; Bo Li; Qingquan Liu
Journal:  Front Pharmacol       Date:  2019-12-23       Impact factor: 5.810

8.  A case of pheochromocytoma crisis with persistent hypotension successfully managed with vasopressin.

Authors:  Daigo Chiba; Yurika Hada; Kenji Numahata; Akihiro Ito
Journal:  Urol Case Rep       Date:  2021-03-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.